News | July 10, 2024
Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection
The Unit has been issued GMP Certification from ANVISA-Brazil
The Unit has been issued GMP Certification from ANVISA-Brazil
This product will be manufactured at Lupin’s Pithampur facility in India
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Laurus Labs receives EIR from USFDA for API facilities
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Subscribe To Our Newsletter & Stay Updated
